SRSD Inc

1. Teva Pharmaceuticals USA, Inc. $2,843,351 227 payments
2. ITI, Inc. $1,025,244 289 payments
3. AbbVie, Inc. $572,694 25 payments
4. Otsuka Pharmaceutical Development & Commercialization, Inc. $562,722 21 payments
5. Hoffmann-La Roche Limited $388,877 17 payments
6. Sumitomo Pharma America, Inc. $261,612 10 payments
7. Boehringer Ingelheim Pharmaceuticals, Inc. $234,691 11 payments
8. Janssen Research & Development, LLC $183,360 23 payments
9. Sage Therapeutics, Inc. $129,898 29 payments
10. Roche TCRC, Inc. $121,227 13 payments

1. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $2,139,245 165 payments
2. Iti-007-451 $845,054 275 payments
3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $595,142 40 payments
4. Acute Schizophrenia Study $362,440 12 payments
5. A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $309,135 4 payments
6. A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder $296,044 2 payments
7. An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication $145,897 3 payments
8. PoC in Prevention of Relapse $136,747 3 payments
9. A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation $128,835 14 payments
10. The Effect of 24Week Treatment With Basmisanil on Cognitive Impairment Associated With Schizophrenia $121,227 13 payments

1. Other $64,911 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.